Avandia Lawsuit Settled Case Loans

Have a Settled Avandia Lawsuit? Need Cash Now?

TriMark Legal Funding provides post-settlement funding on settled Avandia lawsuits nationwide.

Legal Funding on Avandia Lawsuits

TriMark Legal Funding is one of America’s foremost legal funding companies. We provide settled case funding on settled Avandia litigation nationwide.

At TriMark Legal Funding, we offer non-recourse lawsuit funding cash advances to plaintiffs who are involved in either pending or settled legal claims, often in 24 hours or less.

Lawsuit loans are a discreet, sensible way to keep your head above water until your attorney has finished negotiating your lawsuit settlement.

Get Help With Legal Funding

Have questions about legal funding? Just complete this form, and a member of our team will call you back to answer them.
(* required)

Leave this field blank
If legal funding is not available or your case is ineligible, would you like to be notified about other funding options you may be eligible for? *

Have Questions?
Call and speak with one of our funding experts today.

Important Notice About Avandia Lawsuit Funding

TriMark Legal Funding only offers post-settlement funding on settled Avandia lawsuits at this time

This means that to qualify for funding consideration, you must have already signed your settlement agreement and know either

  1. The gross amount of your settlement OR
  2. The actual net amount you will be receiving after all deductions (attorney fees, case costs, medical liens, etc.)

If you have a settled Avandia lawsuit and would like to apply for settlement funding, please apply here.

How Lawsuit Loans Work

TriMark Legal Funding specializes in helping personal injury accident victims.
Our non-recourse legal funding is a simple 3-step process:

1. Apply for Funding

You can either apply online or call us toll-free at (877) 932-2628. We’ll answer all of your questions and gather some basic facts about your case.

2. Review & Approval

Our team will work directly with your attorney to review your case. Approvals can happen as quickly as 1 hour after receipt of all required information.

3. Receive Cash

A funding agreement is sent via DocuSign. After signed copies are returned, your cash is sent to you by wire transfer or FedEx Overnight.

Avandia Lawsuit Funding

Are you currently waiting on an Avandia settlement because you suffered injuries or side effects from taking the prescription drug? Could you really use some of your future settlement money right now? TLF is one of the nation’s leading providers of Avandia settlement funding; pre-settlement and post-settlement.

What Is Avandia?

Studies have confirmed that the popular diabetic drug Avandia (a generic name is Rosiglitazone) has been linked to a number of serious and life-threatening cardiac risks and consequences. 

Avandia (Rosiglitazone) is a member of class of drugs called Thiazolidinediones, or TZDs.  It was approved by the FDA in 1999.  It was released by GlaxoSmithKline (GSK) for the treatment of Type-2 diabetes as either a stand-alone medication or in combination with Metformin (Avandamet) or with Glimepiride (Avandaryl).

The Controversy

In 2007, more than eight years after Rosiglitazone was first introduced onto the market, a study conducted by Dr. Steven Nissen at the Cleveland Clinic made public the serious heart risks associated with the drug’s use.  Dr. Nissen analyzed data that was handed over to the FDA in 2005.  The data suggested that taking Avandia significantly increased the risk of heart attacks and heart-related deaths by over 40% and 60%, respectively.  Dr. Nissen’s study was published in the New England Journal of Medicine (NEJM), a well-respected peer-reviewed medical journal.

Largely in response to this study, in 2007 the FDA reevaluated Avandia and confirmed Nissen’s findings. Nissen’s study further spurred a Senate Finance Committee investigation into the drug and its side effects. 

The two-year investigation culminated in a 342-page report that concluded there was sufficient evidence to suggest that GSK was aware of the association between the drug and its cardiac risks several years prior to Nissen’s study becoming public.  In fact, the evidence even suggested that GSK knew of the risks possibly as early as 1999, almost the same time the drug was approved by the FDA. 

The Senate’s report further argued that the company had a duty to sufficiently warn patients and the FDA of its concerns because the report indicates “GSK executives intimidated independent physicians, focused on strategies to minimize findings that Avandia may increase cardiovascular risk, and sought ways to downplay findings that the rival drug ACTOS (Pioglitazone) might reduce cardiovascular risk.”

Avandia Side Effects

In addition to the increased risks of heart attack, stroke, and other cardiac events, some of the more common side effects include upper respiratory infections (cold-like symptoms); headaches; weight gain; back pain; anemia (low red blood cell count); bone fractures, hypoglycemia (low blood sugar), with symptoms of nervousness, sweating, intense hunger, trembling, weakness, or palpitations. Here is the full list of side effects.

Numerous lawsuits are currently pending against GSK, the manufacturer, alleging that it knew about severe adverse side effects and failed to disclose them to the FDA and the general public. Potentially serious side effects can include:

  • Myocardial Infarction (Heart Attack)
  • Congestive Heart Failure
  • Edema, and Fluid Retention
  • Cerebral Vascular Disease (Stroke)
  • Other Myocardial Ischemic Related Events

The most significant side effect observed in clinical trials has been heart attacks and heart failures.

In studies involving over 14,000 patients, the results showed that users suffered 43% more heart attacks than those on a placebo.

Since its inception, the drug has been prescribed to millions of Americans and has generated as much as $3.2 billion per year in sales, as of 2006 and $1.19 billion as of 2009. Experts believe the drug is responsible for hundreds of thousands of cardiovascular problems in the U.S. from 1999 to 2009.

Is A Recall On The Horizon?

A public safety advisory was issued in 2007 to warn patients of the cardiovascular risks associated with the drug’s use. The FDA however, has refused to issue a recall, claiming that sufficient evidence as to the dangers versus the benefits of the drug does not exist.

Avandia Settlements

As of July 2010, GSK has set aside $460 million to settle lawsuits filed by some 10,000 patients (an average of over $40 thousand per plaintiff) and thousands of more injured patients are gearing up to sue GSK over the drug.


  • Abilify
  • Accutane
  • Actonel
  • Actos
  • Androgel
  • Avandia
  • Avelox
  • Baycol
  • Belviq
  • Bextra
  • Boniva
  • Celebrex
  • Cipro
  • Coumadin
  • Crestor
  • Darvocet
  • Darvon
  • Dexatrim
  • Dexilant
  • Eliquis
  • Ephedrine
  • Fen-Phen
  • Fluoroquinolones
  • Fosamax
  • Gadolinium Dye
  • GranuFlo & NaturaLyte
  • Heparin
  • Invokana
  • Levaquin
  • Lipitor
  • Lipobay
  • Losartan
  • Meridia
  • Nexium
  • Paxil
  • Pergolide
  • Permax
  • Plavix
  • Prempro
  • Prevacid
  • Prexige
  • Prilosec
  • Propulsid
  • Proton Pump Inhibitors (PPI)
  • Protonix
  • Prozac
  • Raptiva
  • Ranitidine
  • Reglan
  • Rezulin
  • RotaShield
  • Seldane
  • Seroquel
  • Taxotere
  • Testosterone
  • Topomax
  • Trasylol
  • Trovan
  • Truvada
  • Valsartan
  • Vioxx
  • Warfarin
  • Yasmin
  • Yaz
  • Zantac
  • Zelnorm
  • Zocor
  • Zofran
  • Zoloft
  • Zyban
  • Zyprexa

Medical Devices

  • Bair Hugger
  • ERCP Scope
  • Guidant Heart Device
  • IUD Litigation
    • Mirena IUD
    • Paragard IUD
  • Kugel Mesh Patch
  • Medtronic
    • Infuse Bone Graft
    • Marquis Defibrillator
    • Sprint Fidelis
  • NuvaRing
  • Ortho Evra Patch
  • Phillips CPAP
  • Power Morcellator
  • Surgical Robot
    • Da Vinci Robot

Products / Other

  • 9/11 First Responder Settlements
  • Big Tobacco
  • Class Action Lawsuits
  • Commercial Litigation Funding
  • Deepwater Horizon MDL 2179
  • Dow Corning Breast Implant
  • DuPont C-8 (Teflon) MDL 2433
  • E-Cigarettes
    • JUUL
  • FIU Bridge Collapse
  • Hertz False Arrest Lawsuit
  • Iraq War Hostages
  • Paraquat Weedkiller
  • PG&E Wildfire Lawsuits
  • Sports Injury Lawsuits
    • NCAA Concussion
    • NFL Concussion
    • WWE Concussion
  • Takata Airbag Settlement

Apply For Avandia Lawsuit Settled Case Funding

Lawsuit Funding FAQ Apply Now

To qualify for an Accutane lawsuit cash advance, you must have a settled Avandia lawsuit. Pending lawsuits are not eligible at this time.

To qualify, you must have an already signed Avandia settlement agreement which clearly shows either the gross amount of your settlement or the actual net amount you will be receiving after all deductions (attorney fees, case costs, medical liens, etc.) have been made.

If you have a settled Avandia lawsuit and need funding, either:

Call Us At (877) 932-2628 or

Latest Developments in the Avandia Lawsuit…

In the largest settlement involving a pharmaceutical company, the British drugmaker GlaxoSmithKline agreed to plead guilty to criminal charges and pay $3 billion in fines for promoting its best-selling antidepressants for unapproved uses and failing to report safety data about a top diabetes drug, federal prosecutors announced Monday. The agreement also includes civil penalties for improper marketing of a half-dozen other drugs. The fine against GlaxoSmithKline over Paxil, Wellbutrin, Avandia and the other drugs makes this year a record for money recovered by the federal government under its so-called whistle-blower law, according to a group that tracks such numbers. In May, Abbott Laboratories settled for $1.6 billion over its marketing of the antiseizure drug Depakote. And an agreement with Johnson & Johnson that could result in a fine of as much as $2 billion is said to be imminent over its off-label promotion of an antipsychotic drug, Risperdal. No individuals… Read more
The British drug company GlaxoSmithKline said Thursday that it had agreed to pay $3 billion to settle United States government civil and criminal investigations into its sales practices for numerous drugs. The settlement would be the largest yet in a wave of federal cases against pharmaceutical companies accused of illegal marketing, surpassing the previous record of $2.3 billion paid by Pfizer in 2009. In recent years, drug companies have been prime targets of federal fraud investigations, which have recovered tens of billions of dollars for Medicaid and Medicare. The cases against GlaxoSmithKline include illegal marketing of Avandia, a diabetes drug that was severely restricted last year after it was linked to heart risks. Federal prosecutors said the company had paid doctors and manipulated medical research to promote the drug…. Read more
Even for a flush drugmaker like GlaxoSmithKline, $2.4 billion dollars is a lot of money to wipe off the books in a single quarter. Bottles of Avandia diabetes pills are seen at Jack's Pharmacy on May 21, 2007, in San Anselmo, Calif. Justin Sullivan/Getty Images Yet, just hours after a panel of U.S. experts voted in favor of keeping Glaxo's diabetes pill Avandia on the market, despite known heart risks, that's what the drugmaker said it would do in its second quarter. All that money wil go to cover the cost of a bunch of legal problems, including the settlement of lawsuits over harm allegedly linked to Avandia. The company said "the substantial majority of the product liability cases relating to Avandia have now been settled." Glaxo hasn't disclosed how much money that involves. But Bloomberg reported the company has already agreed to pay about $460 million to put those… Read more
A draft study by an FDA scientist has linked side effects of Avandia to tens of thousands of heart problems among elderly users, and suggests that more than 100,000 Americans may have suffered heart attacks, strokes or other problems from Avandia since the drug was introduced. The draft Avandia study (pdf) was performed by drug safety reviewers from FDA and the Centers for Medicare and Medicaid Services (CMS). According to a story by Pharmalot, a drug reviewer at the FDA is pushing for the study to be published in a medical journal in the near future, while the FDA is continuing its own analysis of the safety of GlaxoSmithKline’s diabetes drug. The researchers performed an observational study looking at data from more than 227,000 Avandia users over the age of 65 and compared those with users of the competing diabetes drug Actos, by Takeda Pharmaceuticals. They found that in that age group, Avandia increased the… Read more
If you’ve read the news lately, you may have heard that GlaxoSmithKline agreed to settle approximately 700 Avandia lawsuits for a reported $60 million. You may also have heard the calls to end the Avandia safety trial known as the TIDE trial. This may have you concerned about how these developments affect you, and rightfully so. GlaxoSmithKline has reportedly agreed to settle 700 lawsuits for approximately $60 million. How this settlement affects you depends on where you are in the lawsuit process, if you are involved at all. Obviously, if you’re one of the 700 lawsuits that have been settled, then your lawsuit is now done; you’ll receive your share of the settlement and no longer have to worry about the litigation. If you are one of the remaining lawsuits (reported to number in the thousands), how this settlement affects you is less clear. Details about the settlement have been… Read more
GlaxoSmithKline faces a U.S. investor lawsuit claiming that Europe's biggest drugmaker misled shareholders about the safety of diabetes drug Avandia. Law firm Kaplan Fox & Kilsheimer said in a statement it had filed a class action suit in the U.S. District Court for the Southern District of New York against Glaxo and certain of its officers alleging the company had made false statements. The suit claims Glaxo failed adequately to disclose the fact that it had performed a pooled, or meta, analysis that showed Avandia increased the risk of heart attacks. Glaxo publicly disclosed its meta-analysis only after top U.S. cardiologist Steven Nissen published his own meta-analysis on heart-attack risk last month, which sent shares in the British-based drugmaker tumbling. Kaplan Fox & Kilsheimer said … Read more

See More